Physician profile
Mohammad Fazel
NPI 1437447745
$460.53
in general payments reported to CMS, 2019-2025
11 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $52.38 · 2022: $25.62 · 2024: $33.36 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.77 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $99.00 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $74.90 | 2019-2020 | |
| Genzyme Corporation | $55.52 | 2019-2024 | |
| Dusa Pharmaceuticals, INC. | $40.68 | 2019 | |
| Lilly USA, LLC | $35.07 | 2019-2020 | |
| Amgen INC. | $30.92 | 2025 | Otezla |
| Helsinn Therapeutics (U.S.), INC. | $29.52 | 2019 | |
| Ucb, INC. | $27.03 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.46 | 2025 | |
| Abbvie INC. | $25.62 | 2022 | |
| Leo Pharma INC. | $15.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Fazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.